Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06721494

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

California Clinical Trials Medical Group

Glendale, California, 91206, United States

Location status: Recruiting

Location contact

Lev Gertsik, M.D.

CONTACT

[email protected]

888-228-7425

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Major Inclusion Criteria:

  • Healthy participants aged 18 to 55 years, inclusive;
  • Meets DSM-5 criteria for methamphetamine use disorder;
  • Not seeking treatment for methamphetamine use disorder;
  • Primary route of methamphetamine self-administration must be intravenous or smoking;
  • Able to abstain from methamphetamine without experiencing severe withdrawal;
  • A body mass index between 18 to 30 kg/m2, inclusive and a minimum body weight of 56 kg;
  • Females must not be lactating and must have a negative pregnancy test during screening and admission.

Major Exclusion Criteria:

  • Estimated glomerular filtration rate <60 mL/min/1.73 m2;
  • History of cardiovascular disease;
  • Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;
  • History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.

Treatment and study plan

Methamphetamine

Drug

Methamphetamine HCl for intravenous administration

Sterile Saline

Drug

Sterile Saline for intravenous administration

CS-1103

Drug

CS-1103 for intravenous administration

Primary outcomes

  1. Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations

    Time frame: 3 days plus follow-up on Day 10

    Physical examinations

  2. Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)

    Time frame: 3 days plus follow-up on Day 10

    Digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted.

  3. Number of participants with CS-1103-related adverse events (AEs) assessed by vital signs

    Time frame: 3 days plus follow-up on Day 10

    Blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature

  4. Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parameters

    Time frame: 3 days plus follow-up on Day 10

    Clinical chemistry, hematology, coagulation, and urinalysis

  5. Time course and magnitude of urine excretion of methamphetamine

    Time frame: 48 hours

    Measurement of concentration of methamphetamine in urine

Secondary outcomes

  1. Time course of CS-1103 blood and urine concentrations

    Time frame: 48 hours

    Measurement of plasma and urine concentrations of CS-1103

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Del Rosario, B.S.

CONTACT

[email protected]

617-621-8500

Piercen Oliver, Ph.D.

CONTACT

[email protected]

617-621-8500

Sponsors and collaborators

Lead sponsor

Clear Scientific, Inc.

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 6, 2024
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.